Synthesis and Optimization of the Docetaxel-Loaded and Durvalumab-Targeted Human Serum Albumin Nanoparticles, In Vitro Characterization on Triple-Negative Breast Cancer Cells-Reference-Cited by-同舟云学术

Synthesis and Optimization of the Docetaxel-Loaded and Durvalumab-Targeted Human Serum Albumin Nanoparticles, In Vitro Characterization on Triple-Negative Breast Cancer Cells

Published:2023-07-13 Issue:29 Volume:8 Page:26287-26300
ISSN:2470-1343
Container-title:ACS Omega
language:en
Short-container-title:ACS Omega

Author:

Yurt Fatma¹^ORCID,Özel Derya¹,Tunçel Ayça¹,Gokbayrak Ozde²,Aktas Safiye²

Affiliation:

1. Department of Nuclear Applications, Institute of Nuclear Science, Ege University, Bornova, 35100 Izmir, Turkey

2. Department of Basic Oncology, Institute of Oncology, DokuzEylül University, 35340 Izmir, Turkey

Funder

Ege ?niversitesi

Publisher

American Chemical Society (ACS)

Subject

General Chemical Engineering,General Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsomega.3c02682

Reference62 articles.

1. Recent Advances in Cancer Therapy: An Overview

2. Multifunctional nanoparticles for cancer immunotherapy

3. Nanomedicine applications in the treatment of breast cancer: current state of the art

4. In Vivo Targeted Delivery of Nanoparticles for Theranosis

5. Nanocarriers as an emerging platform for cancer therapy

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The use of nanomaterials as drug delivery systems and anticancer agents in the treatment of triple-negative breast cancer: an updated review (year 2005 to date);Discover Nano;2024-09-03

2. Enhanced anticancer effect of newly synthesised albumin-bound Fe(III)-S-Methyl-thiosemicarbazones on breast cancer cells;Journal of Taibah University for Science;2024-07-15

3. Recent advances in albumin nanoparticle-based cancer therapies;Journal of Pharmaceutical Investigation;2024-07-05

4. Macrophage derived Exosomal Docetaxel (Exo-DTX) for pro-metastasis suppression: QbD driven formulation development, validation, in-vitro and pharmacokinetic investigation;European Journal of Pharmaceutics and Biopharmaceutics;2024-02

5. Durvalumab and taxane family combination therapy enhances the antitumoral effects for NSCLC: An in vitro study;Cell Biochemistry and Function;2024-01